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SUMMARY
Objective: To evaluate the effects of high-dose isoflavones on the uterus of castrated adult 
rats. Methods: Adult, ovariectomized virgin rats (n = 40) were treated by gavage during 
30 consecutive days with vehicle (propylene glycol, group GCtrl) or different doses of 
genistein: 42 (group GES42), 125 (GES125), or 250 (GES250) μg/g body weight per day. 
Animals were killed, weighed, vaginal and uterine samples were taken for cytologic eval-
uation, and serum levels of 17 β-estradiol and progesterone were determined. The mid-
dle third of the uterine horns was dissected, fixed in 10% formaldehyde and processed 
for paraffin inclusion; 5-μm thick sections were obtained and stained with HE for further 
histological study under light microscopy. The endometrial morphology and area, num-
ber and area of glands, and number of eosinophils in the lamina propria were analyzed. 
ANOVA and the Tukey-Kramer test were used for statistical analyses. Results: Uterine 
weight, endometrial glandular area, and number of glands and eosinophils were all high-
er in GES250 > G125 than in the other groups (GES250 > GES125 > GES42 = GCtrl; 
p  <  0.05). Morphological data showed signs of endometrial proliferation upon treat-
ment with genistein, especially in animals in GES125 and GES250 compared to other 
groups. In all animals in GES250, signs of uterine squamous metaplasia were observed. 
Conclusion: A short treatment period with high daily doses of isoflavones can promote 
endometrial squamous metaplasia in ovariectomized rats. 
Keywords: Isoflavones; ovariectomy; uterus; metaplasia; rats.
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INTRODUCTION
Atrophy of the female genital tract secondary to hypoes-
trogenism, usually associated with vaginal or urinary 
symptoms, such as desiccation, pruritus, discomfort, dis-
paurenia, dysuria, and urinary urgency, is common aTher 
menopause1. Besides, hypoestrogenism can cause differ-
ent organic changes that can lead to the development of 
vasomotor symptoms, cardiovascular diseases, osteopo-
rosis, cognitive dysfunction, loss of bone mass, and uro-
genital changes2.
Hormone replacement therapy (HRT) is the classical 
treatment for relief of postmenopausal vasomotor symp-
toms, especially hot flashes and urogenital atrophy. How-
ever, due to possible adverse effects on the breasts and 
uterus, i.e., higher rate of breast cancer and endometrial 
hyperplasia, investigators have been searching for other 
therapeutic alternatives3,4.
Over the last few years, isoflavones became an alter-
native to HRT because they are considered safer, they are 
estrogen agonists, and have weak intrinsic activity5. Isofla-
vones are the most studied phytotherapeutic agents, be-
ing found mainly in soy, and their main active elements 
include genistein, daidzein, biochanin A, and formonone-
tin6. Genistein is the most active one and is found in large 
quantities in soy7.
However, despite several clinical assays having inves-
tigated its efficacy, most of them were unable to demon-
strate its action on vaginal epithelium nor that it counter-
acts vasomotor symptoms8,9. Chiechi et al.10 reported that 
post-menopausal isoflavones for long periods have trophic 
effects on the vaginal epithelium. The authors attributed 
this fact to prolonged exposure to dietary phytoestrogens. 
On the other hand, Ferrari11 reported that high-dose iso-
flavones, genistein in particular, can be used to treat hot 
flashes in post-menopausal women, with a good safety 
profile.
Epidemiological studies showed that phytoestrogens 
are associated with a reduction in the risk of estrogen-
dependent cancer12,13. In vitro studies, especially with ge-
nistein, have demonstrated induction of apoptosis in cells 
with estrogen receptors in breast and cervical tumors14.
Several in vivo studies, especially in rats, have demon-
strated a trophic action of isoflavones on the female genital 
tract. However, the response of this system to high doses 
was not properly assessed15-17. The objective of the present 
study was to investigate the actions of high-dose isofla-
vones on endometrial morphology in rats.
METHODS
This is an experimental, prospective, double-blind, 
randomized study with adult virgin female rats (Rat-
tus norvegicus albinus), weighing approximately 250  g, 
furnished by the Experimentation Model Develop-
ment Center (CEDEME) of Universidade Federal de São 
Paulo – Escola Paulista de Medicina (UNIFESP – EPM). 
This study was approved by the Ethics on Research Com-
mittee of UNIFESP/EPM (protocol #0749/07).
DRUG
The soy extract used in this study had a total of 42.6% of 
isoflavones. Approximately 36% were genistein, 62%, daid-
zein, and 2%, glycitein (including isoflavones isoforms). 
Four per cent of the remaining extract 57 was composed 
of proteins (Zhonshan Road, Dalian, China).
ANIMALS
Forty virgin adult female rats, approximately 90 days old, 
weighing a mean of 250  g, of the Wistar EPM-1 lineage 
(Rattus norvegicus albinus) were used. Animals were ini-
tially taken to the Histology and Structural Biology De-
partment Bioterium, being confined in plastic cages with 
metal grates at 22°C under artificial light (Philips fluores-
cent light bulbs – mode daylight with potency of 40 W) 
with daylight-dark periods of 12 hours each. Animals un-
derwent colpocytologic tests for 21 consecutive days, and 
those in normal estrous cycle underwent bilateral ovari-
ectomy.
Twenty-eight days aTher the ovariectomy, animals were 
randomly divided into four groups: GCtrl (control) – re-
ceived propylene glycol; GES42 – received 42 μg/g per day 
of genistein; GES125 – received 125 μg/g per day of genis-
tein; and GES250 – received 250 μg/g per day of genistein.
The drug was administered daily during a 30-day peri-
od diluted in 1.0 mL of propylene glycol and administered 
by gavage at the beginning of the daylight period, around 
7 a.m.
In the last week, colpocytologic exams were performed 
daily and stained by the Harris-Shorr method to assess 
stimulation of the phytohormone. For this purpose, a cot-
ton swab (cotonette®) embedded in saline was introduced 
in the vaginal ostium. Material from the vaginal lumen 
was collected and placed on a glass slide, which was im-
mediately immersed in ethanol and ether solution (1:1) 
for 10 minutes. At the end of this period, the material was 
stained by the Shorr-Harris method.
SAMPLE COLLECTING PROCEDURES
Thirty days aTher the onset of drug administration, all ani-
mals were weighed on semi-analytic scales and anesthe-
tized with xylazine (20 mg/kg) and ketamine (100 mg/kg) 
intraperitoneally. Soon aTher, blood was drawn by car-
diac puncture and the serum was separated and stored 
at -20°C until determination of 17β-estradiol (E2) and 
progesterone (P4).
ATher a longitudinal incision of the abdomen, the 
uterus was removed. ATherwards, animals were euthanized 
with deepening of the anesthetic plane. Immediately aTher 
removal, the uterus was dissected and the adipose tissue 
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was removed. The material was then weighed on a preci-
sion scale (Mettler-Toledo®), its middle third was removed 
and immersed in 10% formaldehyde for 24 hours. Tissue 
samples were dehydrated in increasing concentrations of 
ethylic alcohol and diaphanized in xylene. Samples were, 
then, processed for paraffin inclusion. Transversal samples 
were obtained perpendicular to the greater axis of the 
uterine horn and stained by hematoxylin-eosin (HE).
HORMONE ANALYSIS
Serum levels of 17β-estradiol (E2) and progesterone (P4) 
were determined. Aer the blood was drawn, it was cen-
trifuged at 4°C (1500 × g) for 10 minutes and the superna-
tant was frozen at -20°C until it was analyzed by radioim-
munoassay (RIA) using the double-antibody technique in 
precoated tubes (ICN Biomedical Inc., Costa Mera, CA, 
USA) according to manufacturer’s recommendations. As-
says were performed in duplicate. Samples were processed 
on the same day. The mean detection limit for E2 and P4 
was 0.1 pg/mL and 0.1 ng/mL, respectively.
HISTOLOGICAL ANALYSIS
Morphologic assessment was performed with light mi-
croscopy using a Carl Zeiss® microscope with objective 
lenses of 10 × magnification and ocular lenses of 10 and 
40  × magnification. Mophometric assessment was per-
formed by image digitalization with the Carl Zeiss® Axio-
Vision sofiware 4.1. The area occupied by the endometri-
um and glands in each histological slide from each animal 
slide was evaluated.
The areas to be evaluated were determined using a 
mouse and calculated automatically by the Carl Zeiss® 
AxioVision sofiware 4.1. This procedure was performed 
to measure the areas occupied by the endometrium and 
endometrial glands in each histological slide of the uterus 
of each rat. The number of eosinophils was assessed by 
counting four fields, one in each quadrant of each histo-
logical slide, in a 500-μm2 area in each quadrant. Four his-
tological slides from each animal were evaluated.
STATISTICAL ANALYSIS
The data underwent analysis of variance (ANOVA), which 
was complemented by the Tukey-Kramer test for multiple 
comparisons. The level of significance of a null hypothesis 
was 5% (p < 0.05).
RESULTS
WEIGHT
Rats treated with isoflavones had lower body weight; howev-
er, this data was not significantly different among the groups 
analyzed. On the other hand, the weight of the uterus was 
increased in GES250 and GES150 compared to the others 
(GES250 > GES125 > GES42 = GCtrl, p < 0.05) (Table 1).
HORMONE LEVELS AND COLPOCYTOLOGY
Serum levels of 17β-estradiol (E2) and progesterone (P4) 
among the different groups did not show variations (Ta-
ble  1). Among animals in the CGtrl and GES42 groups, 
vaginal cytology showed very few cells, some of which 
were phagocytes (Figures  1A and B). In GES125 and 
GES250, the test showed large amounts of polyhedral, 
anucleated, acidophilic cells from the superficial layers 
(Figures 1C and D).
MORPHOLOGY
On morphologic analysis the uterus of animals in the con-
trol group (GCtrl) and GES42 had basically the same as-
pect, i.e., slim and atrophic with few endometrial glands. 
 Study groups
 GCtrl GES42 GES125 GES250
Body weight (g) 238.5 ± 24.4 227.3 ± 33.9 214.2 ± 22.1 217.4 ± 23.9
Uterine weight (g) 2.7 ± 0.5a 3.2 ± 0.8a 6.2 ± 1.1b 9.5 ± 1.3c
Estradiol (pg/mL) 2.5 ± 0.4 3.0 ± 1.1 2.8 ± 1.3 3.4 ± 1.6
Progesterone (ng/mL) 1.4 ± 0.3 1.6 ± 0.9 1.9 ± 0.8 1.7 ± 1.5
Squamous metaplasia 0/10 0/10 0/10 10/10
Endometrium    
Area x 105 (μm²) 3.75 ± 1.49a 4.39 ± 1.10a 11.03 ± 4.64b 23.11 ± 5.67c
Number of endometrial glands/area  
(nr./104μm²)
7.40 ± 3.33a 6.23 ± 3.47a 10.30 ± 2.21b 13.2 ± 3.21b
Area of endometrial glands (104μm2) 0.32 ± 0.12a 0.35 ± 0.11a 0.77 ± 0.21b 1.77 ± 0.42c
Eosinophils (nr./500μm²) 22.50 ± 8.06a 25.83 ± 5.21a 54.90 ± 14.19b 85.60 ± 11.12c
Superscript letters indicate statistical comparison: c > b > a, p < 0.05. G, group; Ctrl, control; ES42 = 42 μg of genistein; ES125 = 125 μg of 
genistein; ES250 = 250 μg of genistein.
Table 1 – Body weight, uterine weight, serum levels of 17ß-estradiol, progesterone, and endometrial morphometry, as well 
as the presence of squamous metaplasia in rats treated with different doses of genistein
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Figure 2 – Microphotographs showing endometrial areas 
from ovariectomized rats and/or treated with different 
concentrations of genistein (G,fi group; Ctrl,fi control; 
ES42fi=fi42fiμg of genistein; ES125fi=fi125fiμg of genistein; 
ES250fi=fi250fiμg of genistein). In A and B, note the 
endometrium covered by superficial (EP) and glandular 
(EG) simple cylindrical epithelium with lamina propria with 
large concentration of cells with heterochromatic nuclei 
(arrow head). In C, note superficial (RP) and glandular 
(EG) epithelium with large euchromatic nuclei (arrows). 
In D and E, observe superficial (EP) and glandular (EG) 
non-keratinized stratified squamous epithelium (EP). In D, 
note superficial epithelial sprouting into the lamina propria 
(arrows). Harris-Shorr, 400X. Barfi=fi20fiμm.
The endometrium was covered by a simple cubic epithe-
lium and by squamous epithelium in some areas. The lam-
ina propria contained countless cells with round, markedly 
stained nuclei and very little cytoplasm (Figures 2A and B). 
In GES125 and GES250, enlarged uteri with thicker layers 
were observed. In GES125, uteri were covered by a simple 
prismatic epithelium. Lamina propria contained cells with 
large, clear nuclei and pronounced nucleoli. A large con-
centration of endometrial glands constituted by large cubic 
cells was observed. In the endometrial stroma, we noted 
countless eosinophils (Figure 2C). In GES250, the uterus 
was even larger than in other groups, with a viscous clear 
fluid, and it was covered by simple prismatic epithelium 
and, in some areas, non-keratinized stratified squamous 
epithelium, indicating the presence of squamous metapla-
sia (Figure 2D). In most animals (n = 8), prominences were 
observed on the base of the superficial epithelium in the 
direction of the lamina propria (Figure 2D). Endometrial 
glands were dilated and constituted by large cuboidal cells, 
and in some areas by non-keratinized stratified squamous 
epithelium, indicating squamous metaplasia (Figure  2E). 
In the lamina propria, a large concentration of eosinophils 
was observed, some infiltrating the superficial or glandular 
epithelium (Figures 2D and E).
HISTOMORPHOMETRY
Morphometric analysis of the endometrium demon-
strated greater endometrial area, greater number and 
area occupied by endometrial glands, as well as greater 
number of eosinophils in the GES250 then in the other 
groups (GES250 > GES125 > GES42 = GCtrl; p < 0.05) 
(Table 1).
DISCUSSION
Aer publication of the WHI (Women’s Health Initiative) 
study, there was a considerable increase in prescription 
of isoflavones and other drugs, since the aforementioned 
clinical assay demonstrated that menopausal hormonal 
therapy with continuous estrogens and medroxyprogeste-
rone was associated with higher risk of breast cancer and 
thromboembolism18. Since then, isoflavones became an 
interesting therapeutic alternative in postmenopausal wo-
men with symptoms of hypoestrogenism.
However, the clinical impact of using isoflavones is still 
controversial. In regard to its effects on the breasts, Wood 
et al.19 observed it has an anti-estrogenic effect while other 
authors observed estrogenic effects. As for the endome-
trium, Unfer et al.20 reported greater risk of endometrial 
hyperplasia in long-term users.
To investigate the effects of high-dose of isoflavones in 
the uterus of ovariectomized rats, we performed the pres-
ent study. For such, we used rats aer 28 days post-ovari-
ectomy. This period corresponds to the hypoestrogenism 
state in postmenopausal females21.
Soy extract was administered in this study as source of 
isoflavones. The dose was determined based on previous 
study on the subject where, using the same extract in rats, 
the dose-effect curve regarding the colpocytologic exam 
and weight of the uterus was determined22. The doses se-
lected were based on the following parameters: one dose 
Figure 1 – Microphotographs showing colpocytology of ovari-
ectomized rats and/or treated with different concentrations of 
genistein (G,figroup; Ctrl,ficontrol; ES42fi=fi42fiμg of genistein; 
ES125fi=fi125fiμg of genistein; ES250fi=fi250fiμg of genistein). 
In A and B, note the scarcity of cells from desquamation of 
the vaginal epithelium and countless leucocytes (arrows). In 
C and D, observe anucleated acidophil epithelial cells from 
more superficial layers of the vaginal epithelium, and in D, 
large cell concentration. Harris-Shorr, 400X. Barfi=fi20fiμm.
(A)
(C) (D)
(B)
(A)
(C) (D) (E)
(B)
(GCtrl)
(ES125) (ES250) (ES250)
(ES42)
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that did not change the weight of the uterus neither the 
colpocytologic exam (42 μg/g); and one smaller dose capa-
ble of changing the weight of the uterus and keratinization 
of the vaginal epithelium (125 μg/g). A dose twice as high 
as the latter was considered a high-dose22.
As expected in our experiment, an increase in the 
weight of the uterus was observed in animals in GES125 
and GES250 compared to the control and GES42. These 
data suggest that the doses of isoflavones used affected the 
uterus promoting dose-dependent trophic changes. Those 
findings were reported by Ishimi et al.23, Picherit et al.24, 
and Uesugi et al.25 who also noticed a dose-dependent tro-
phic effect on the uterus when evaluating the effects of ge-
nistein on prevention of bone mass in castrated rats.
Hormone levels (17β-estradiol and progesterone) were 
low and significant changes were not observed among the 
different groups. However, colpocytopathological aspects 
showed that 125 and 250  μg/g of isoflavones had dose-
dependent proliferative and differentiating actions on 
vaginal epithelium, since the colpocytologic exam showed 
large concentration of anucleated acidophil cells.
Studies have demonstrated that prolonged exposure 
of rats to diets containing isoflavones increases uterine 
sensitivity to those substances, an effect that is mediated 
by nuclear estrogen-specific receptors. The mechanism of 
action of isoflavones on target tissue results in estrogen 
and anti-estrogen effects, among others, depending on the 
type and concentration of the stimulated receptor on tis-
sues and their concentration in the body26. Currently, iso-
flavones are considered natural selective estrogen receptor 
modulators (SERMs)6,27.
Isoflavones have greater affinity for β  estrogen re-
ceptors (ERβ)28, which are less frequent in the endome-
trium and breasts than  receptors (ER)29. Its activity is 
500-1000 times weaker than endogenous estrogens, but 
isoflavones can produce the same levels of estradiol bioac-
tivity, as long as they are used in concentrations high enou-
gh to achieve the maximum response. That indicates that 
estrogen receptors and receptor-isoflavonoid complex are 
functionally equivalent30. Note that Möller et al.31 reported 
that the chronic ingestion of isoflavones increase dramati-
cally the receptivity of β estrogen receptors in rat uterus. 
Apart from the classical mechanism of hormone action 
(genomic), one should consider the presence of estro-
gen receptors on the cellular membrane (GPR30/GPRE), 
as well as β receptors (monomers) bound to the internal 
surface of the cell membrane. Those present non-genomic 
immediate effects32.
Our results showed uterine hypertrophy with endo-
metrial epithelial squamous metaplasia, both on superfi-
cial and glandular epithelium, in all animals treated with 
high-doses of isoflavones (250 μg/kg). These data suggest 
that this dose of isoflavones has endometrial proliferative 
effects. In fact, experimental studies with different doses 
of isoflavones reported different actions on endometrial 
tissue32-34. Thus, the minimum dose usually used in hu-
mans does not show any morphologic changes. On the 
other hand, high-doses like those used in the GES250 
group caused metaplastic changes in rat endometrium.
Studies with 395 postmenopausal women who re-
ceived 70 mg/kg of isoflavones for three months showed 
relative endometrial safety without any mitogenic effects, 
being considered safe both to the endometrium and the 
breasts. However, there is a lack of data on long-term en-
dometrial effects.
Sacks et al.35 suggested that the use of isoflavones sup-
plements both in foods and in pills is not recommended. 
On the other hand, the actions of several soy products 
considered beneficial for cardiovascular health are based 
on their high contents of polyunsaturated fats, fibers, vita-
mins, minerals, and low contents of saturated fats and not 
on their genistein content.
CONCLUSION
Our results lead to the conclusion that administration of 
soy extract to ovariectomized rats at a dose of 125  μg/g 
of genistein had uterotrophic effects. Those include incre-
ased endometrial area, and number of glands and eosi-
nophils. High-doses (250 μg/g of genistein) triggered the 
development of squamous metaplasia in all animals, in 
addition to the uterotrophic effects.
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